Targets › VEGFB
1 program from 1 company in 1 trial: 1 Phase 4; Ophthalmology.
Growth factor for endothelial cells. VEGF-B167 binds heparin and neuropilin-1 whereas the binding to neuropilin-1 of VEGF-B186 is regulated by proteolysis. (UniProt, P49765)
Open in Phaseline: the race on VEGFB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai Eye Disease Prevention and Treatment Center | Conbercept Vascular endothelial growth factor A inhibitor; Vascular endothelial growth factor B inhibitor; Placenta growth factor inhibitor | VEGFA, VEGFB, PGF, VEGFC | Phase 4 | Diabetic Macular Edema | – |
Diabetic Macular Edema (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.